HCV E2 Antikörper (N-Term)

Produktnummer ABIN966020

Produktdetails anti-HCV E2 Antikörper

Target: HCV E2 (Hepatitis C Virus Envelope Protein E2 (HCV E2))

Bindungsspezifität: N-Term

Reaktivität: Hepatitis C Virus (HCV)

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser HCV E2 Antikörper ist unkonjugiert

Applikation: Immunohistochemistry (IHC)

Aufreinigung: Purified by antigen-specific affinity chromatography.

Immunogen: Polyclonal antibody produced in rabbits immunizing with a synthetic peptide corresponding to N-terminal residues of Hepatitis C virus envelope E2 protein.

Anwendungsinformationen

Applikationshinweise: ELISA, Western blotting: 1µg/ml for 2hrs.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: This antibody is stored in PBS, 50% glycerol

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C

Referenzen für anti-HCV E2 Antikörper (ABIN966020)

Bukh, Apgar, Engle, Govindarajan, Hegerich, Tellier, Wong, Elkins, Kew: "Experimental infection of chimpanzees with hepatitis C virus of genotype 5a: genetic analysis of the virus and generation of a standardized challenge pool." in: The Journal of infectious diseases, Vol. 178, Issue 4, pp. 1193-7, (1998) (PubMed).

Kolykhalov, Agapov, Blight, Mihalik, Feinstone, Rice: "Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA." in: Science (New York, N.Y.), Vol. 277, Issue 5325, pp. 570-4, (1997) (PubMed).

Details zu HCV E2

Target: HCV E2 (Hepatitis C Virus Envelope Protein E2 (HCV E2))

Andere Bezeichnung: E2 (HCV E2 Produkte)

Substanzklasse: Viral Protein

Hintergrund: Envelope glycoproteins E1 and E2 are involved in virus attachment to the host cell as well as in virus endocytosis and fusion with host membrane. E2 inhibits human EIF2AK2/PKR activation, preventing the establishment of an antiviral state. E2 is a viral ligand for CD209/DC-SIGN and CLEC4M/DCSIGNR, which are respectively found on dendritic cells (DCs), and on liver sinusoidal endothelial cells and macrophage-like cells of lymph node sinuses. These interactions allow capture of circulating HCV particles by these cells and subsequent transmission to permissive cells. DCs are professional antigen presenting cells, critical for host immunity by inducing specific immune responses against a broad variety of pathogens. They act as sentinels in various tissues where they entrap pathogens and convey them to local lymphoid tissue or lymph node for establishment of immunity. Capture of circulating HCV particles by these SIGN+ cells may facilitate virus infection of proximal hepatocytes and lymphocyte subpopulations and may be essential for the establishment of persistent infection.